Omega-3 fatty acids in neurodegenerative diseases: Focus on mitochondria

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 88, Issue 1, 2013, Pages 105-114

  Eckert, Gunter P ^a   Lipka, Uta ^a   Muller, Walter E ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

ALA; Alzheimer; ARA; Arachidonic acid; Brain; Brain aging; Clinic; DHA; Diet; Docosahexaenoic acid; Eicosahexaenoic acid; EPA; Fatty acids; Huntington; Linoleic acid; Linolenic acid; Mitochondria; Neurodegeneration; Nutrition; Omega 3; Parkinson; PUFA; Stroke

Indexed keywords

DOCOSAHEXAENOIC ACID; ETHYL DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; ICOSAPENTAENOIC ACID ETHYL ESTER; LONG CHAIN FATTY ACID; OMEGA 3 FATTY ACID; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

AEROBIC METABOLISM; AGING; ALZHEIMER DISEASE; ARTICLE; BRAIN ISCHEMIA; BRAIN MITOCHONDRION; DEGENERATIVE DISEASE; DIET SUPPLEMENTATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; FAT INTAKE; FATTY ACID METABOLISM; HUMAN; HUNTINGTON CHOREA; LIPID PEROXIDATION; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL;

AGING; ANIMALS; BRAIN; DIETARY SUPPLEMENTS; FATTY ACIDS, OMEGA-3; HUMANS; MITOCHONDRIA; MITOCHONDRIAL DISEASES; NEURODEGENERATIVE DISEASES; NEURONS; NEUROPROTECTIVE AGENTS;

ANIMALIA;

EID: 84872007389     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2012.05.006     Document Type: Article

References (214)

1. Bourre J.M. Roles of unsaturated fatty acids (especially omega-3 fatty acids) in the brain at various ages and during ageing. J. Nutr. Health Aging 2004, 8:163-174.
2. Haag M. Essential fatty acids and the brain. Can. J. Psychiatry 2003, 48:195-203.
3. Moore S.A. Polyunsaturated fatty acid synthesis and release by brain-derived cells in vitro. J. Mol. Neurosci. 2001, 16:195-200.
4. Gao F., Kim H.W., Igarashi M., et al. Liver conversion of docosahexaenoic and arachidonic acids from their 18-carbon precursors in rats on a DHA-free but alpha-LNA-containing n-3 PUFA adequate diet. Biochim. Biophys. Acta 2011, 1811:484-489.
5. Fu Z., Attar-Bashi N.M., Sinclair A.J. 1-14C-linoleic acid distribution in various tissue lipids of guinea pigs following an oral dose. Lipids 2001, 36:255-260.
6. Eckert G.P., Franke C., Noldner M., et al. Plant derived omega-3-fatty acids protect mitochondrial function in the brain. Pharmacol. Res. 2010, 61:234-241.
7. Igarashi M., Ma K., Chang L., Bell J.M., Rapoport S.I. Dietary n-3 PUFA deprivation for 15 weeks upregulates elongase and desaturase expression in rat liver but not brain. J. Lipid Res. 2007, 48:2463-2470.
8. Igarashi M., DeMar J.C., Ma K., Chang L., Bell J.M., Rapoport S.I. Upregulated liver conversion of alpha-linolenic acid to docosahexaenoic acid in rats on a 15 week n-3 PUFA-deficient diet. J. Lipid Res. 2007, 48:152-164.
9. Ikemoto A., Nitta A., Furukawa S., et al. Dietary n-3 fatty acid deficiency decreases nerve growth factor content in rat hippocampus. Neurosci. Lett. 2000, 285:99-102.
10. Barcelo-Coblijn G., Collison L.W., Jolly C.A., Murphy E.J. Dietary alpha-linolenic acid increases brain but not heart and liver docosahexaenoic acid levels. Lipids 2005, 40:787-798.
11. Taha A.Y., Filo E., Ma D.W., McIntyre Burnham W. Dose-dependent anticonvulsant effects of linoleic and alpha-linolenic polyunsaturated fatty acids on pentylenetetrazol induced seizures in rats. Epilepsia 2009, 50:72-82.
12. Diwakar B.T., Dutta P.K., Lokesh B.R., Naidu K.A. Bio-availability and metabolism of n-3 fatty acid rich garden cress (Lepidium sativum) seed oil in albino rats. Prostaglandins Leukot Essent Fatty Acids 2008, 78:123-130.
13. Barcelo-Coblijn G., Kitajka K., Puskas L.G., et al. Gene expression and molecular composition of phospholipids in rat brain in relation to dietary n-6 to n-3 fatty acid ratio. Biochim. Biophys. Acta 2003, 1632:72-79.
14. Q. Du, J.C. Martin, G. Agnani, et al., Dairy fat blends high in alpha-linolenic acid are superior to n-3 fatty-acid-enriched palm oil blends for increasing DHA levels in the brains of young rats, J. Nutr. Biochem., in press (2012).
15. D. Arsenault, C. Julien, C.T. Chen, R.P. Bazinet, F. Calon, Dietary intake of unsaturated fatty acids modulates physiological properties of entorhinal cortex neurons in mice, J. Neurochem., in press, http://dx.doi.org/10.1111/j.1471-4159.2012.07772.x.
16. Rosell M.S., Lloyd-Wright Z., Appleby P.N., Sanders T.A., Allen N.E., Key T.J. Long-chain n-3 polyunsaturated fatty acids in plasma in British meat-eating, vegetarian, and vegan men. Am. J. Clin. Nutr. 2005, 82:327-334.
17. Alessandri J.M., Guesnet P., Vancassel S., et al. Polyunsaturated fatty acids in the central nervous system: evolution of concepts and nutritional implications throughout life. Reprod. Nutr. Dev. 2004, 44:509-538.
18. Mazza M., Pomponi M., Janiri L., Bria P., Mazza S. Omega-3 fatty acids and antioxidants in neurological and psychiatric diseases: an overview. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006, 31:12-26.
19. Bourre J.M. Effects of Nutrients (in Food) on the structure and function of the nervous system: update on dietary requirements for brain. Part 1: Micronutrients. J. Nutr. Health Aging. 2006, 10:377-385.
20. Bazan N.G., Musto A.E., Knott E.J. Endogenous signaling by omega-3 docosahexaenoic acid-derived mediators sustains homeostatic synaptic and circuitry integrity. Mol. Neurobiol. 2011, 44:216-222.
21. Kim H.Y., Spector A.A., Xiong Z.M. A synaptogenic amide N-docosahexaenoylethanolamide promotes hippocampal development. Prostaglandins Other Lipid. Mediat. 2011, 96:114-120.
22. Yehuda S., Rabinovitz S., Mostofsky D.I. Essential fatty acids are mediators of brain biochemistry and cognitive functions. J. Neurosci. Res. 1999, 56:565-570.
23. Litman B.J., Mitchell D.C. A role for phospholipid polyunsaturation in modulating membrane protein function. Lipids 1996, 31(Suppl):S193-S197.
24. Kitajka K., Puskas L.G., Zvara A., et al. The role of n-3 polyunsaturated fatty acids in brain: modulation of rat brain gene expression by dietary n-3 fatty acids. Proc. Nat. Acad. Sci. U.S.A. 2002, 99:2619-2624.
25. Beltz B.S., Tlusty M.F., Benton J.L., Sandeman D.C. Omega-3 fatty acids upregulate adult neurogenesis. Neurosci. Lett. 2007, 415:154-158.
26. Kawakita E., Hashimoto M., Shido O. Docosahexaenoic acid promotes neurogenesis in vitro and in vivo. Neuroscience 2006, 139:991-997.
27. Robson L.G., Dyall S., Sidloff D., Michael-Titus A.T. Omega-3 polyunsaturated fatty acids increase the neurite outgrowth of rat sensory neurones throughout development and in aged animals. Neurobiol. Aging. 2008, 31:678-687.
28. Sakamoto T., Cansev M., Wurtman R.J. Oral supplementation with docosahexaenoic acid and uridine-5'-monophosphate increases dendritic spine density in adult gerbil hippocampus. Brain Res. 2007, 1182:50-59.
29. Jiang L.H., Shi Y., Wang L.S., Yang Z.R. The influence of orally administered docosahexaenoic acid on cognitive ability in aged mice. J. Nutr. Biochem. 2009, 20:735-741.
30. Fedorova I., Hussein N., Di M.C., et al. An n-3 fatty acid deficient diet affects mouse spatial learning in the Barnes circular maze. Prostaglandins Leukot. Essent. Fatty Acids 2007, 77:269-277.
31. Vancassel S., Leman S., Hanonick L., et al. n-3 polyunsaturated fatty acid supplementation reverses stress-induced modifications on brain monoamine levels in mice. J. Lipid Res. 2008, 49:340-348.
32. Ozyurt B., Sarsilmaz M., Akpolat N., et al. The protective effects of omega-3 fatty acids against MK-801-induced neurotoxicity in prefrontal cortex of rat. Neurochem. Int. 2007, 50:196-202.
33. Bazan N.G. Neuroprotectin D1-mediated anti-inflammatory and survival signaling in stroke, retinal degenerations, and Alzheimer's disease. J. Lipid Res. 2009, 50(Suppl):S400-405.
34. Lukiw W.J., Bazan N.G. Docosahexaenoic acid and the aging brain. J. Nutr. 2008, 138:2510-2514.
35. Flachs P., Horakova O., Brauner P., et al. Polyunsaturated fatty acids of marine origin upregulate mitochondrial biogenesis and induce beta-oxidation in white fat. Diabetologia 2005, 48:2365-2375.
36. Jeng J.Y., Yeh T.S., Chiu Y.H., Lee Y.C., Cheng H.H., Hsieh R.H. Linoleic acid promotes mitochondrial biogenesis and maintains mitochondrial structure for prevention of streptozotocin damage in RIN-m5F cells. Biosci. Biotechnol. Biochem. 2009, 73:1262-1267.
37. Yeh Y.Y., Gehman M.F., Yeh S.M. Maternal dietary fish oil enriches docosahexaenoate levels in brain subcellular fractions of offspring. J. Neurosci. Res. 1993, 35:218-226.
38. Brenna J.T., Diau G.Y. The influence of dietary docosahexaenoic acid and arachidonic acid on central nervous system polyunsaturated fatty acid composition. Prostaglandins Leukot. Essent. Fatty Acids 2007, 77:247-250.
39. Suzuki H., Manabe S., Wada O., Crawford M.A. Rapid incorporation of docosahexaenoic acid from dietary sources into brain microsomal, synaptosomal and mitochondrial membranes in adult mice. Int. J. Vitam. Nutr. Res. 1997, 67:272-278.
40. Smeitink J., van den Heuvel L., DiMauro S. The genetics and pathology of oxidative phosphorylation. Nat. Rev. Genet. 2001, 2:342-352.
41. Harper M.E., Bevilacqua L., Hagopian K., Weindruch R., Ramsey J.J. Ageing, oxidative stress, and mitochondrial uncoupling. Acta Physiol. Scand. 2004, 182:321-331.
42. Fukai T., Ushio-Fukai M. Superoxide dismutases: role in redox signaling, vascular function, and diseases. Antioxid Redox Signal 2011, 15:1583-1606.
43. Garrel C., Alessandri J.M., Guesnet P., Al-Gubory K.H. Omega-3 fatty acids enhance mitochondrial superoxide dismutase activity in rat organs during post-natal development. Int. J. Biochem. Cell. Biol. 2012, 44:123-131.
44. Lee H.P., Pancholi N., Esposito L., et al. Early induction of oxidative stress in mouse model of Alzheimer disease with reduced mitochondrial superoxide dismutase activity. PLoS One 2012, 7:e28033.
45. Muller W.E., Eckert A., Kurz C., Eckert G.P., Leuner K. Mitochondrial dysfunction: common final pathway in brain aging and Alzheimer's disease-therapeutic aspects. Mol. Neurobiol. 2010, 41:159-171.
46. Piergiacomi V.A., Palacios A., Catala A. Comparative studies on lipid peroxidation of microsomes and mitochondria obtained from different rat tissues: effect of retinyl palmitate. Prostaglandins Leukot Essent Fatty Acids 2001, 64:75-80.
47. Infante J.P., Huszagh V.A. Secondary carnitine deficiency and impaired docosahexaenoic (22:6n-3) acid synthesis: a common denominator in the pathophysiology of diseases of oxidative phosphorylation and beta-oxidation. FEBS Lett. 2000, 468:1-5.
48. Marchetti P., Castedo M., Susin S.A., et al. Mitochondrial permeability transition is a central coordinating event of apoptosis. J. Exp. Med. 1996, 184:1155-1160.
49. Green D.R., Reed J.C. Mitochondria and apoptosis. Science 1998, 281:1309-1312.
50. Reed J.C. Bcl-2 family proteins. Oncogene 1998, 17:3225-3236.
51. Manero F., Gautier F., Gallenne T., et al. The small organic compound HA14-1 prevents Bcl-2 interaction with Bax to sensitize malignant glioma cells to induction of cell death. Cancer Res. 2006, 66:2757-2764.
52. An J., Chen Y., Huang Z. Critical upstream signals of cytochrome c release induced by a novel Bcl-2 inhibitor. J. Biol. Chem. 2004, 279:19133-19140.
53. Hao J.H., Yu M., Liu F.T., Newland A.C., Jia L. Bcl-2 inhibitors sensitize tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by uncoupling of mitochondrial respiration in human leukemic CEM cells. Cancer Res. 2004, 64:3607-3616.
54. Wang J.L., Liu D., Zhang Z.J., et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc. Nat. Acad. Sci. U.S.A. 2000, 97:7124-7129.
55. Eckert A., Keil U., Marques C.A., et al. Mitochondrial dysfunction, apoptotic cell death, and Alzheimer's disease. Biochem. Pharmacol. 2003, 66:1627-1634.
56. Cory S., Huang D.C., Adams J.M. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003, 22:8590-8607.
57. Tamatani M., Ogawa S., Niitsu Y., Tohyama M. Involvement of Bcl-2 family and caspase-3-like protease in NO-mediated neuronal apoptosis. J. Neurochem. 1998, 71:1588-1596.
58. Lonergan P.E., Martin D.S., Horrobin D.F., Lynch M.A. Neuroprotective effect of eicosapentaenoic acid in hippocampus of rats exposed to gamma-irradiation. J. Biol. Chem. 2002, 277:20804-20811.
59. Lonergan P.E., Martin D.S., Horrobin D.F., Lynch M.A. Neuroprotective actions of eicosapentaenoic acid on lipopolysaccharide-induced dysfunction in rat hippocampus. J. Neurochem. 2004, 91:20-29.
60. Delerive P., Fruchart J.C., Staels B. Peroxisome proliferator-activated receptors in inflammation control. J. Endocrinol. 2001, 169:453-459.
61. Sampath H., Ntambi J.M. Polyunsaturated fatty acid regulation of gene expression. Nutr. Rev. 2004, 62:333-339.
62. Cullingford T.E. The ketogenic diet; fatty acids, fatty acid-activated receptors and neurological disorders. Prostaglandins Leukot.Essent.Fatty Acids 2004, 70:253-264.
63. Puskas L.G., Bereczki E., Santha M., et al. Cholesterol and cholesterol plus DHA diet-induced gene expression and fatty acid changes in mouse eye and brain. Biochimie 2004, 86:817-824.
64. Inoue I., Shino K., Noji S., Awata T., Katayama S. Expression of peroxisome proliferator-activated receptor alpha (PPAR alpha) in primary cultures of human vascular endothelial cells. Biochem. Biophys. Res. Commun. 1998, 246:370-374.
65. Chambrier C., Bastard J.P., Rieusset J., et al. Eicosapentaenoic acid induces mRNA expression of peroxisome proliferator-activated receptor gamma. Obes. Res. 2002, 10:518-525.
66. Sethi S., Ziouzenkova O., Ni H., Wagner D.D., Plutzky J., Mayadas T.N. Oxidized omega-3 fatty acids in fish oil inhibit leukocyte-endothelial interactions through activation of PPAR alpha. Blood 2002, 100:1340-1346.
67. Armstrong M.B., Towle H.C. Polyunsaturated fatty acids stimulate hepatic UCP-2 expression via a PPARalpha-mediated pathway. Am. J. Physiol. Endocrinol. Metab. 2001, 281:E1197-1204.
68. de Urquiza A.M., Liu S., Sjoberg M., et al. Docosahexaenoic acid, a ligand for the retinoid X receptor in mouse brain. Science 2000, 290:2140-2144.
69. Feng Z., Zou X., Jia H., et al. Maternal docosahexaenoic acid feeding protects against impairment of learning and memory and oxidative stress in prenatally stressed rats: possible role of neuronal mitochondria metabolism. Antioxid Redox Signal 2012, 16:275-289.
70. Song L., Zheng J., Li H., et al. Prenatal stress causes oxidative damage to mitochondrial DNA in hippocampus of offspring rats. Neurochem. Res. 2009, 34:739-745.
71. Filosto M., Scarpelli M., Cotelli M.S., et al. The role of mitochondria in neurodegenerative diseases. J. Neurol 2011, 258:1763-1774.
72. Coskun P., Wyrembak J., Schriner S., et al. A mitochondrial etiology of Alzheimer and Parkinson disease. Biochim. Biophys. Acta 2012, 1820:553-564.
73. Rohrbach S. Effects of dietary polyunsaturated fatty acids on mitochondria. Curr. Pharm. Des. 2009, 15:4103-4116.
74. Palacios-Pelaez R., Lukiw W.J., Bazan N.G. Omega-3 essential Fatty acids modulate initiation and progression of neurodegenerative disease. Mol. Neurobiol. 2010, 41:367-374.
75. Mattson M.P., Chan S.L., Duan W. Modification of brain aging and neurodegenerative disorders by genes, diet, and behavior. Physiol. Rev. 2002, 82:637-672.
76. Mattson M.P., Magnus T. Ageing and neuronal vulnerability. Nat. Rev. Neurosci. 2006, 7:278-294.
77. Stoll S., Scheuer K., Pohl O., Muller W.E. Ginkgo biloba extract (EGb 761) independently improves changes in passive avoidance learning and brain membrane fluidity in the aging mouse. Pharmacopsychiatry 1996, 29:144-149.
78. F. Gao, A.Y. Taha, K. Ma, L. Chang, D. Kiesewetter, S.I. Rapoport, Aging Decreases Rate of Docosahexaenoic Acid Synthesis-Secretion from Circulating Unesterified Alpha-Linolenic Acid by Rat Liver, Age (Dordr), in press (2012).
79. Ruggiero F.M., Cafagna F., Petruzzella V., Gadaleta M.N., Quagliariello E. Lipid composition in synaptic and nonsynaptic mitochondria from rat brains and effect of aging. J. Neurochem. 1992, 59:487-491.
80. Eckert G.P., Wood W.G., Mueller W.E. Effects of aging and beta-amyloid on the properties of brain synaptic and mitochondrial membranes. J. Neural. Transm. 2001, 108:1051-1064.
81. Ochoa J.J., Pamplona R., Ramirez-Tortosa M.C., et al. Age-related changes in brain mitochondrial DNA deletion and oxidative stress are differentially modulated by dietary fat type and coenzyme Q. Free Radical Biol. Med. 2011, 50:1053-1064.
82. Balaban R.S., Nemoto S., Finkel T. Mitochondria, oxidants, and aging. Cell 2005, 120:483-495.
83. Benzi G., Pastoris O., Marzatico F., Villa R.F., Dagani F., Curti D. The mitochondrial electron transfer alteration as a factor involved in the brain aging. Neurobiol. Aging 1992, 13:361-368.
84. Lenaz G., Bovina C., Castelluccio C., et al. Mitochondrial complex I defects in aging. Mol. Cell. Biochem. 1997, 174:329-333.
85. Atamna H., Frey W.H. Mechanisms of mitochondrial dysfunction and energy deficiency in Alzheimer's disease. Mitochondrion 2007, 7:297-310.
86. Martinez M., Ferrandiz M.L., De Juan E., Miquel J. Age-related changes in glutathione and lipid peroxide content in mouse synaptic mitochondria: relationship to cytochrome c oxidase decline. Neurosci. Lett. 1994, 170:121-124.
87. Perluigi M., Di Domenico F., Giorgi A., et al. Redox proteomics in aging rat brain: involvement of mitochondrial reduced glutathione status and mitochondrial protein oxidation in the aging process. J. Neurosci. Res. 2010, 88:3498-3507.
88. Richter C., Park J.W., Ames B.N. Normal oxidative damage to mitochondrial and nuclear DNA is extensive. Proc. Nat. Acad. Sci. U.S.A. 1988, 85:6465-6467.
89. Yao J., Hamilton R.T., Cadenas E., Brinton R.D. Decline in mitochondrial bioenergetics and shift to ketogenic profile in brain during reproductive senescence. Biochim. Biophys. Acta 2010, 1800:1121-1126.
90. Liu X., Shibata T., Hisaka S., Kawai Y., Osawa T. DHA hydroperoxides as a potential inducer of neuronal cell death: a mitochondrial dysfunction-mediated pathway. J. Clin. Biochem. Nutr. 2008, 43:26-33.
91. Eckert G.P., Chang S., Eckmann J., et al. Liposome-incorporated DHA increases neuronal survival by enhancing non-amyloidogenic APP processing. Biochim. Biophys. Acta 2011, 1808:236-243.
92. Leutner S., Eckert A., Mueller W.E. ROS generation, lipid peroxidation and antioxidant enzyme activities in the aging brain. J. Neural. Transm. 2001, 108:955-967.
93. Kurowska E.M., Dresser G.K., Deutsch L., Vachon D., Khalil W. Bioavailability of omega-3 essential fatty acids from perilla seed oil. Prostaglandins Leukot Essent Fatty Acids 2003, 68:207-212.
94. Umezawa M., Kogishi K., Tojo H., et al. High-linoleate and high-alpha-linolenate diets affect learning ability and natural behavior in SAMR1 mice. J. Nutr. 1999, 129:431-437.
95. Okaniwa Y., Yuasa S., Yamamoto N., et al. A high linoleate and a high alpha-linolenate diet induced changes in learning behavior of rats. Effects of a shift in diets and reversal of training stimuli. Biol. Pharm. Bull. 1996, 19:536-540.
96. Kitajka K., Sinclair A.J., Weisinger R.S., et al. Effects of dietary omega-3 polyunsaturated fatty acids on brain gene expression. Proc. Nat. Acad. Sci. U.S.A. 2004, 101:10931-10936.
97. Froyland L., Madsen L., Vaagenes H., et al. Mitochondrion is the principal target for nutritional and pharmacological control of triglyceride metabolism. J. Lipid Res. 1997, 38:1851-1858.
98. Mandard S., Muller M., Kersten S. Peroxisome proliferator-activated receptor alpha target genes. Cell. Mol. Life Sci.: CMLS 2004, 61:393-416.
99. Martin D.S., Lonergan P.E., Boland B., et al. Apoptotic changes in the aged brain are triggered by interleukin-1beta-induced activation of p38 and reversed by treatment with eicosapentaenoic acid. J. Biol. Chem. 2002, 277:34239-34246.
100. Lindberg M., Saltvedt I., Sletvold O., Bjerve K.S. Long-chain n-3 fatty acids and mortality in elderly patients. Am. J. Clin. Nutr. 2008, 88:722-729.
101. Virtanen J.K., Siscovick D.S., Longstreth W.T., Kuller L.H., Mozaffarian D. Fish consumption and risk of subclinical brain abnormalities on MRI in older adults. Neurology 2008, 71:439-446.
102. Andreeva V.A., Kesse-Guyot E., Barberger-Gateau P., Fezeu L., Hercberg S., Galan P. Cognitive function after supplementation with B vitamins and long-chain omega-3 fatty acids: ancillary findings from the SU.FOL.OM3 randomized trial. Am. J. Clin. Nutr. 2011, 94:278-286.
103. Cole G.M., Ma Q.L., Frautschy S.A. Dietary fatty acids and the aging brain. Nutr. Rev. 2010, 68(Suppl 2):S102-111.
104. Shankar G.M., Li S., Mehta T.H., et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 2008, 14:837-842.
105. Lacor P.N., Buniel M.C., Furlow P.W., et al. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J. Neurosci. 2007, 27:796-807.
106. Manczak M., Park B.S., Jung Y., Reddy P.H. Differential expression of oxidative phosphorylation genes in patients with Alzheimer's disease: implications for early mitochondrial dysfunction and oxidative damage. Neuromolecular Med. 2004, 5:147-162.
107. Manczak M., Anekonda T.S., Henson E., Park B.S., Quinn J., Reddy P.H. Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum. Mol. Genet. 2006, 15:1437-1449.
108. Valla J., Berndt J.D., Gonzalez-Lima F. Energy hypometabolism in posterior cingulate cortex of Alzheimer's patients: superficial laminar cytochrome oxidase associated with disease duration. J. Neurosci. 2001, 21:4923-4930.
109. H.B. Schioth, S. Craft, S.J. Brooks, W.H. Frey, 2nd, C. Benedict, Brain Insulin Signaling and Alzheimer's Disease: Current Evidence and Future Directions, Molecular Neurobiol, (2012) in press.
110. Mattson M.P., Gleichmann M., Cheng A. Mitochondria in neuroplasticity and neurological disorders. Neuron 2008, 60:748-766.
111. Hirai K., Aliev G., Nunomura A., et al. Mitochondrial abnormalities in Alzheimer's disease. J. Neurosci. 2001, 21:3017-3023.
112. G.P. Eckert, K. Renner, S.H. Eckert, et al., Mitochondrial dysfunction-a pharmacological target in Alzheimer's disease, Mol. Neurobiol., in press, http://dx.doi.org/10.1007/s12035-012-8271-z.
113. Du H., Guo L., Yan S., Sosunov A.A., McKhann G.M., Yan S.S. Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model. Proc. Nat. Acad. Sci. U.S.A. 2010, 107:18670-18675.
114. Borger E., Aitken L., Muirhead K.E., et al. Mitochondrial beta-amyloid in Alzheimer's disease. Biochem. Soc. Trans. 2011, 39:868-873.
115. Manczak M., Calkins M.J., Reddy P.H. Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer's disease: implications for neuronal damage. Hum. Mol. Genet. 2011, 20:2495-2509.
116. Pavlov P.F., Wiehager B., Sakai J., et al. Mitochondrial gamma-secretase participates in the metabolism of mitochondria-associated amyloid precursor protein. Faseb. J. 2011, 25:78-88.
117. Pagani L., Eckert A. Amyloid-beta interaction with mitochondria. Int. J. Alzheimers Dis. 2011, 2011:925050.
118. K. Leuner, T. Schutt, C. Kurz, et al., Mitochondria-derived ROS lead to enhanced amyloid beta formation, Antioxid Redox. Signal, (2012) in press.
119. Grimm M.O., Kuchenbecker J., Grosgen S., et al. Docosahexaenoic acid reduces amyloid beta production via multiple pleiotropic mechanisms. J. Biol. Chem. 2011, 286:14028-14039.
120. Hashimoto M., Hossain S. Neuroprotective and ameliorative actions of polyunsaturated fatty acids against neuronal diseases: beneficial effect of docosahexaenoic acid on cognitive decline in Alzheimer's disease. J. Pharmacol. Sci. 2011, 116:150-162.
121. Cole G.M., Ma Q.L., Frautschy S.A. Omega-3 fatty acids and dementia. Prostaglandins Leukot Essent Fatty Acids 2009, 81:213-221.
122. Green K.N., Martinez-Coria H., Khashwji H., et al. Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-beta and tau pathology via a mechanism involving presenilin 1 levels. J. Neurosci. 2007, 27:4385-4395.
123. Lim G.P., Calon F., Morihara T., et al. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J. Neurosci. 2005, 25:3032-3040.
124. Perez S.E., Berg B.M., Moore K.A., et al. DHA diet reduces AD pathology in young APPswe/PS1 Delta E9 transgenic mice: possible gender effects. J. Neurosci. Res. 2010, 88:1026-1040.
125. Oster T., Pillot T. Docosahexaenoic acid and synaptic protection in Alzheimer's disease mice. Biochim. Biophys. Acta 2010, 1801:791-798.
126. Arsenault D., Julien C., Tremblay C., Calon F. DHA improves cognition and prevents dysfunction of entorhinal cortex neurons in 3×Tg-AD mice. PLoS One 2011, 6:e17397.
127. Stanley W.C., Khairallah R.J., Dabkowski E.R. Update on lipids and mitochondrial function: impact of dietary n-3 polyunsaturated fatty acids. Curr. Opin. Clin. Nutr. Metab. Care 2012, 15:122-126.
128. Guan Z.Z., Soderberg M., Sindelar P., Edlund C. Content and fatty acid composition of cardiolipin in the brain of patients with Alzheimer's disease. Neurochem. Int. 1994, 25:295-300.
129. Quinn J.F., Raman R., Thomas R.G., et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. Jama 2010, 304:1903-1911.
130. Fotuhi M., Mohassel P., Yaffe K. Fish consumption, long-chain omega-3 fatty acids and risk of cognitive decline or Alzheimer disease: a complex association. Nat. Clin. Pract. Neurol. 2009, 5:140-152.
131. Frautschy S.A., Cole G.M. What was lost in translation in the DHA trial is whom you should intend to treat. Alzheimers Res. Ther. 2011, 3:2.
132. Umhau J.C. Docosahexaenoic acid supplementation and Alzheimer disease. Jama 2011, 305:672.
133. Berr C., Akbaraly T., Arnaud J., Hininger I., Roussel A.M., Barberger Gateau P. Increased selenium intake in elderly high fish consumers may account for health benefits previously ascribed to omega-3 fatty acids. J. Nutr. Health Aging 2009, 13:14-18.
134. Buell J.S., Dawson-Hughes B., Scott T.M., et al. 25-Hydroxyvitamin D, dementia, and cerebrovascular pathology in elders receiving home services. Neurology 2010, 74:18-26.
135. Umhau J.C., Zhou W., Carson R.E., et al. Imaging incorporation of circulating docosahexaenoic acid into the human brain using positron emission tomography. J. Lipid Res. 2009, 50:1259-1268.
136. Yaffe K. Treatment of Alzheimer disease and prognosis of dementia: time to translate research to results. Jama 2010, 304:1952-1953.
137. S.C. Cunnane, R. Chouinard-Watkins, C.A. Castellano, P. Barberger-Gateau, Docosahexaenoic acid homeostasis, brain aging and Alzheimer's disease: can we reconcile the evidence?, Prostaglandins Leukot Essent Fatty Acids, in press (2012).
138. Kones R. Parkinson's disease: mitochondrial molecular pathology, inflammation, statins, and therapeutic neuroprotective nutrition. Nutr. Clin. Pract. 2010, 25:371-389.
139. Dalfo E., Portero-Otin M., Ayala V., Martinez A., Pamplona R., Ferrer I. Evidence of oxidative stress in the neocortex in incidental Lewy body disease. J. Neuropathol Exp. Neurol. 2005, 64:816-830.
140. Fabelo N., Martin V., Santpere G., et al. Severe alterations in lipid composition of frontal cortex lipid rafts from Parkinson's disease and incidental Parkinson's disease. Mol. Med. 2011, 17:1107-1118.
141. Miyake Y., Sasaki S., Tanaka K., et al. Dietary fat intake and risk of Parkinson's disease: a case-control study in Japan. J. Neurol. Sci. 2010, 288:117-122.
142. Aden E., Carlsson M., Poortvliet E., et al. Dietary intake and olfactory function in patients with newly diagnosed Parkinson's disease: a case-control study. Nutr. Neurosci. 2011, 14:25-31.
143. Gao X., Chen H., Fung T.T., et al. Prospective study of dietary pattern and risk of Parkinson disease. Am. J. Clin. Nutr. 2007, 86:1486-1494.
144. Powers K.M., Smith-Weller T., Franklin G.M., Longstreth W.T., Swanson P.D., Checkoway H. Dietary fats, cholesterol and iron as risk factors for Parkinson's disease. Parkinsonism Relat Disord 2009, 15:47-52.
145. Pilsl A., Winklhofer K.F. Parkin, PINK1 and mitochondrial integrity: emerging concepts of mitochondrial dysfunction in Parkinson's disease. Acta Neuropathol. 2012, 123:173-188.
146. Gispert S., Ricciardi F., Kurz A., et al. Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration. PLoS One 2009, 4:e5777.
147. Mann V.M., Cooper J.M., Krige D., Daniel S.E., Schapira A.H., Marsden C.D. Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. Brain 1992, 115(Pt 2):333-342.
148. Rango M., Bonifati C., Bresolin N. Parkinson's disease and brain mitochondrial dysfunction: a functional phosphorus magnetic resonance spectroscopy study. J. Cereb. Blood Flow Metabol.: Off. J. Int. Soc. Cereb. Blood Flow Metabol. 2006, 26:283-290.
149. Vanitallie T.B. Parkinson disease: primacy of age as a risk factor for mitochondrial dysfunction. Metabolism 2008, 57(Suppl 2):S50-55.
150. Bousquet M., Saint-Pierre M., Julien C., Salem N., Cicchetti F., Calon F. Beneficial effects of dietary omega-3 polyunsaturated fatty acid on toxin-induced neuronal degeneration in an animal model of Parkinson's disease. FASEB J. 2008, 22:1213-1225.
151. Hermanson E., Joseph B., Castro D., et al. Nurr1 regulates dopamine synthesis and storage in MN9D dopamine cells. Exp. Cell. Res. 2003, 288:324-334.
152. Bousquet M., Gue K., Emond V., et al. Transgenic conversion of omega-6 into omega-3 fatty acids in a mouse model of Parkinson's disease. J. Lipid Res. 2011, 52:263-271.
153. Ozsoy O., Seval-Celik Y., Hacioglu G., et al. The influence and the mechanism of docosahexaenoic acid on a mouse model of Parkinson's disease. Neurochem. Int. 2011, 59:664-670.
154. Tanriover G., Seval-Celik Y., Ozsoy O., et al. The effects of docosahexaenoic acid on glial derived neurotrophic factor and neurturin in bilateral rat model of Parkinson's disease. Folia Histochem. Cytobiol. 2010, 48:434-441.
155. Samadi P., Gregoire L., Rouillard C., Bedard P.J., Di Paolo T., Levesque D. Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys. Ann. Neurol. 2006, 59:282-288.
156. Luchtman D.W., Meng Q., Song C. Ethyl-eicosapentaenoate (E-EPA) attenuates motor impairments and inflammation in the MPTP-probenecid mouse model of Parkinson's disease. Behav. Brain Res. 2012, 226:386-396.
157. Kabuto H., Amakawa M., Mankura M., Yamanushi T.T., Mori A. Docosahexaenoic acid ethyl ester enhances 6-hydroxydopamine-induced neuronal damage by induction of lipid peroxidation in mouse striatum. Neurochem. Res. 2009, 34:1299-1303.
158. Cansev M., Ulus I.H., Wang L., Maher T.J., Wurtman R.J. Restorative effects of uridine plus docosahexaenoic acid in a rat model of Parkinson's disease. Neurosci. Res. 2008, 62:206-209.
159. M. Bousquet, K. Gue, V. Emond, et al., Transgenic conversion of omega-6 into omega-3 fatty acids in a mouse model of Parkinson's disease, J. Lipid Res., (2010).
160. Yakunin E., Loeb V., Kisos H., et al. Alpha-Synuclein Neuropathology is Controlled by Nuclear Hormone Receptors and Enhanced by Docosahexaenoic Acid in A Mouse Model for Parkinson's Disease. Brain Pathol. 2012, 22:280-294.
161. Kim K.Y., Stevens M.V., Akter M.H., et al. Parkin is a lipid-responsive regulator of fat uptake in mice and mutant human cells. J. Clin. Invest. 2011, 121:3701-3712.
162. Rappley I., Myers D.S., Milne S.B., et al. Lipidomic profiling in mouse brain reveals differences between ages and genders, with smaller changes associated with alpha-synuclein genotype. J. Neurochem. 2009, 111:15-25.
163. Zigoneanu I.G., Yang Y.J., Krois A.S., Haque E., Pielak G.J. Interaction of alpha-synuclein with vesicles that mimic mitochondrial membranes. Biochim. Biophys. Acta 2012, 1818:512-519.
164. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes The Huntington's Disease Collaborative Research Group. Cell 1993, 72:971-983.
165. DiFiglia M., Sapp E., Chase K.O., et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997, 277:1990-1993.
166. Chang D.T., Rintoul G.L., Pandipati S., Reynolds I.J. Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons. Neurobiol. Dis. 2006, 22:388-400.
167. Li H., Li S.H., Yu Z.X., Shelbourne P., Li X.J. Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice. J. Neurosci. 2001, 21:8473-8481.
168. Vonsattel J.P., Myers R.H., Stevens T.J., Ferrante R.J., Bird E.D., Richardson E.P. Neuropathological classification of Huntington's disease. J. Neuropathol Exp. Neurol. 1985, 44:559-577.
169. Stine O.C., Pleasant N., Franz M.L., Abbott M.H., Folstein S.E., Ross C.A. Correlation between the onset age of Huntington's disease and length of the trinucleotide repeat in IT-15. Hum. Mol. Genet. 1993, 2:1547-1549.
170. Vonsattel J.P., DiFiglia M. Huntington disease. J. Neuropathol. Exp. Neurol. 1998, 57:369-384.
171. Browne S.E. Mitochondria and Huntington's disease pathogenesis: insight from genetic and chemical models. Ann. N Y Acad. Sci. 2008, 1147:358-382.
172. Lin M.T., Beal M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006, 443:787-795.
173. Oliveira J.M. Nature and cause of mitochondrial dysfunction in Huntington's disease: focusing on huntingtin and the striatum. J. Neurochem. 2010, 114:1-12.
174. Reddy P.H., Mao P., Manczak M. Mitochondrial structural and functional dynamics in Huntington's disease. Brain Res. Rev. 2009, 61:33-48.
175. Rosenstock T.R., Duarte A.I., Rego A.C. Mitochondrial-associated metabolic changes and neurodegeneration in Huntington's disease-from clinical features to the bench. Curr. Drug. Targets 2010, 11:1218-1236.
176. Costa V., Giacomello M., Hudec R., et al. Mitochondrial fission and cristae disruption increase the response of cell models of Huntington's disease to apoptotic stimuli. EMBO Mol. Med. 2010, 2:490-503.
177. Goebel H.H., Heipertz R., Scholz W., Iqbal K., Tellez-Nagel I. Juvenile Huntington chorea: clinical, ultrastructural, and biochemical studies. Neurology 1978, 28:23-31.
178. Kim J., Moody J.P., Edgerly C.K., et al. Mitochondrial loss, dysfunction and altered dynamics in Huntington's disease. Hum. Mol. Genet. 2010, 19:3919-3935.
179. Shirendeb U., Reddy A.P., Manczak M., et al. Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage. Hum. Mol. Genet. 2011, 20:1438-1455.
180. Song W., Chen J., Petrilli A., et al. Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity. Nat. Med. 2011, 17:377-382.
181. Tellez-Nagel I., Johnson A.B., Terry R.D. Studies on brain biopsies of patients with Huntington's chorea. J. Neuropathol. Exp. Neurol. 1974, 33:308-332.
182. Wang H., Lim P.J., Karbowski M., Monteiro M.J. Effects of overexpression of huntingtin proteins on mitochondrial integrity. Hum. Mol. Genet. 2009, 18:737-752.
183. Orr A.L., Li S., Wang C.E., et al. N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. J. Neurosci. 2008, 28:2783-2792.
184. Trushina E., Dyer R.B., Badger J.D., et al. Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Mol. Cell. Biol. 2004, 24:8195-8209.
185. Gines S., Seong I.S., Fossale E., et al. Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice. Hum. Mol. Genet. 2003, 12:497-508.
186. Choo Y.S., Johnson G.V., MacDonald M., Detloff P.J., Lesort M. Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum. Mol. Genet. 2004, 13:1407-1420.
187. 2+ in transgenic Huntington disease rats. J. Biol. Chem. 2008, 283:30715-30724.
188. Turner C., Schapira A.H. Mitochondrial matters of the brain: the role in Huntington's disease. J. Bioenerg. Biomembr. 2010, 42:193-198.
189. Clifford J.J., Drago J., Natoli A.L., et al. Essential fatty acids given from conception prevent topographies of motor deficit in a transgenic model of Huntington's disease. Neuroscience 2002, 109:81-88.
190. Van Raamsdonk J.M., Pearson J., Rogers D.A., et al. Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease. Exp. Neurol. 2005, 196:266-272.
191. Vaddadi K.S., Soosai E., Chiu E., Dingjan P. A randomised, placebo-controlled, double blind study of treatment of Huntington's disease with unsaturated fatty acids. Neuroreport 2002, 13:29-33.
192. Puri B.K., Bydder G.M., Counsell S.J., et al. MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment. Neuroreport 2002, 13:123-126.
193. Puri B.K., Leavitt B.R., Hayden M.R., et al. Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial. Neurology 2005, 65:286-292.
194. Murck H., Manku M. Ethyl-EPA in Huntington disease: potentially relevant mechanism of action. Brain Res. Bull. 2007, 72:159-164.
195. Group T.H.S. Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. Arch. Neurol. 2008, 65:1582-1589.
196. Eltzschig H.K., Eckle T. Ischemia and reperfusion--from mechanism to translation. Nat. Med. 2011, 17:1391-1401.
197. Niizuma K., Endo H., Chan P.H. Oxidative stress and mitochondrial dysfunction as determinants of ischemic neuronal death and survival. J. Neurochem. 2009, 109(Suppl 1):133-138.
198. Sun D., Gilboe D.D. Ischemia-induced changes in cerebral mitochondrial free fatty acids, phospholipids, and respiration in the rat. J. Neurochem. 1994, 62:1921-1928.
199. Nakahara I., Kikuchi H., Taki W., et al. Degradation of mitochondrial phospholipids during experimental cerebral ischemia in rats. J. Neurochem. 1991, 57:839-844.
200. Chauveau F., Cho T.H., Perez M., et al. Brain-targeting form of docosahexaenoic acid for experimental stroke treatment: MRI evaluation and anti-oxidant impact. Curr. Neurovascular Res. 2011, 8:95-102.
201. Pan H.C., Kao T.K., Ou Y.C., et al. Protective effect of docosahexaenoic acid against brain injury in ischemic rats. J. Nutr. Biochem. 2009, 20:715-725.
202. Lalancette-Hebert M., Julien C., Cordeau P., et al. Accumulation of dietary docosahexaenoic acid in the brain attenuates acute immune response and development of postischemic neuronal damage. Stroke 2011, 42:2903-2909.
203. Belayev L., Khoutorova L., Atkins K.D., et al. Docosahexaenoic acid therapy of experimental Ischemic stroke. Transl. Stroke Res. 2011, 2:33-41.
204. Mehta S.L., Li P.A. Neuroprotective role of mitochondrial uncoupling protein 2 in cerebral stroke. J. Cereb. Blood. Flow Metab. 2009, 29:1069-1078.
205. Nakase T., Yoshida Y., Nagata K. Amplified expression of uncoupling proteins in human brain ischemic lesions. Neuropathology 2007, 27:442-447.
206. Haines B.A., Mehta S.L., Pratt S.M., Warden C.H., Li P.A. Deletion of mitochondrial uncoupling protein-2 increases ischemic brain damage after transient focal ischemia by altering gene expression patterns and enhancing inflammatory cytokines. J. Cereb. Blood. Flow Metab. 2010, 30:1825-1833.
207. Davis L.M., Rho J.M., Sullivan P.G. UCP-mediated free fatty acid uncoupling of isolated cortical mitochondria from fasted animals: correlations to dietary modulations. Epilepsia 2008, 49(Suppl 8):117-119.
208. Yang D.Y., Pan H.C., Yen Y.J., et al. Detrimental effects of post-treatment with fatty acids on brain injury in ischemic rats. Neurotoxicology 2007, 28:1220-1229.
209. Serkov I.V., Shevtsova E.F., Dubova L.G., et al. Interaction of docosahexaenoic acid derivatives with mitochondria. Dokl. Biol. Sci. 2007, 414:187-189.
210. Simon J.A., Fong J., Bernert J.T., Browner W.S. Serum fatty acids and the risk of stroke. Stroke 1995, 26:778-782.
211. Poppitt S.D., Howe C.A., Lithander F.E., et al. Effects of moderate-dose omega-3 fish oil on cardiovascular risk factors and mood after ischemic stroke: a randomized, controlled trial. Stroke 2009, 40:3485-3492.
212. Garbagnati F., Cairella G., De Martino A., et al. Is antioxidant and n-3 supplementation able to improve functional status in poststroke patients? Results from the Nutristroke Trial. Cerebrovasc Dis. 2009, 27:375-383.
213. Tanaka K., Ishikawa Y., Yokoyama M., et al. Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial. Stroke 2008, 39:2052-2058.
214. Saremi A., Arora R. The utility of omega-3 fatty acids in cardiovascular disease. Am. J. Ther. 2009, 16:421-436.